• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    La Jolla Pharmaceutical Company Receives Orphan Designation from FDA for LJPC-0118

    Jocelyn Aspa
    Jul. 23, 2019 09:08AM PST
    Pharmaceutical Investing

    La Jolla Pharmaceutical (NASDAQ:LJPC) has announced that the US Food and Drug Administration (FDA) has granted the company orphan drug designation for its investigational drug product, LJPC-0229 to treat malaria. As quoted in the press release: “The granting of orphan drug status is a significant milestone for the LJPC-0118 program and highlights the significant unmet …

    La Jolla Pharmaceutical (NASDAQ:LJPC) has announced that the US Food and Drug Administration (FDA) has granted the company orphan drug designation for its investigational drug product, LJPC-0229 to treat malaria.

    As quoted in the press release:

    “The granting of orphan drug status is a significant milestone for the LJPC-0118 program and highlights the significant unmet medical need for the treatment of malaria,” said George Tidmarsh, M.D., Ph.D., La Jolla’s President and Chief Executive Officer. “There are currently no approved treatments in the U.S. for patients with severe malaria. We are preparing to file a new drug application later this year and, upon approval, to making this front-line treatment for severe malaria available to the public.”

    The FDA Orphan Drug Designation Program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. Orphan Drug Designation conveys up to seven years of marketing exclusivity if the sponsor is the first to obtain regulatory approval from the FDA and offers various development incentives, including tax credits related to clinical trial expenses, an exemption from the FDA-user fee and FDA assistance in clinical trial design. The Orphan Drug Designation does not change the standards for approval.

    Click here to read the full press release.

    nasdaq:ljpcpharmaceutical investingus food and drug administrationorphan drug designation
    The Conversation (0)

    Go Deeper

    AI Powered
    Scientist with petri dish.

    Pharma Market Forecast: Top Trends for Pharma in 2025

    Pharma Outlook

    Pharma Outlook

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Invion Limited

    IVX:AU

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×